Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors.

Background: Casirivimab-imdevimab has been developed to neutralize SARS-CoV-2. The global clinical trials in outpatients documented several adverse effects (AE), which mandate caution in Japan where part of patients return home. To investigate post-infusion clinical events and their risk factors, we attempted a retrospective study.

Interprofessional Antimicrobial Stewardship Influencing Infection: An 8-Year Study Using Antimicrobial Use Density.

Purpose: To reduce infection (CDI), we implemented interprofessional antimicrobial, infection control, and diagnostic stewardship (ipAS) conducted by physicians/pharmacists, infection control nurses, and medical technologists, respectively. As a numerical indicator for ipAS, we used antimicrobial use density (AUD) in an 8-year study to validate its efficacy in CDI reduction.

Patients And Methods: This was an observational study.